Journal
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
Volume 37, Issue 6, Pages 1982-1987Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/147323000903700636
Keywords
TYPE 2 DIABETES; PROTEINURIA; DOXAZOSIN; alpha(1)-ADRENERGIC RECEPTOR INHIBITOR; IMMUNOMODULATION; LYMPHOCYTES; REGULATORY T-CELLS
Funding
- [OTKA76316]
- [OM0094-135-163/2008]
Ask authors/readers for more resources
Doxazosin, an alpha(1)-adrenergic receptor inhibitor, is commonly administered to patients with type 2 diabetes, hypertension and nephropathy. The impact of 3 months' doxazosin therapy on the prevalence of activated and regulatory T lymphocytes was analysed in this pilot study of men with type 2 diabetes (n = 10) who received doxazosin 4 mg/day in addition to their ongoing therapy. The prevalence of CD4(+), CD8(+), CD25(+) and CD69(+) cells at baseline and after 3 months of add-on therapy was determined. The prevalence of regulatory T-cells was detected by two different approaches: forkhead box P3 (FoxP3) positivity; and the number of CD4(+)CD25(+high) cells. During 3 months of doxazosin therapy, patients' blood pressure, blood glucose control and lipid profiles all significantly improved. Simultaneously, the prevalence of activated T-cells (CD4(+)CD69(+) and CD8(+)CD69(+) cells) decreased, whereas that of regulatory T-cells increased. These results indicate an immunomodulatory action of doxazosin in type 2 diabetic patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available